Therapeutic effect of rosuvastatin on inflammatory factor levels,insulin resistance and vascular endo-thelial function in patients with hypertension complicated dyslipidemia
10.3969/j.issn.1008-0074.2015.06.18
- VernacularTitle:瑞舒伐他汀对高血压伴血脂异常患者的炎症因子、胰岛素抵抗以及血管内皮功能的疗效
- Author:
Shengyao BAI
;
Ying LIU
;
Hong ZHANG
;
Xuemei ZHANG
- Publication Type:Journal Article
- Keywords:
Hypertension;
Dyslipidemias;
Rosuvastatin
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2015;24(6):647-650
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze therapeutic effect of rosuvastatin on inflammatory factor levels ,insulin resistance (IR) and vascular endothelial function in patients with hypertension complicated dyslipidemia .Methods:A total of 136 outpatients with hypertension complicated dyslipidemia were selected .According to random number table ,they were divided and equally into routine treatment group (received routine therapy ) and rosuvastatin group (received rosuvastatin based on routine treatment ) .Serum levels of C reactive protein (CRP) ,interleukin‐6 (IL‐6) and IL‐8 , IR and vascular endothelial function were compared between two groups before and after treatment .Results:Com‐pared with before treatment ,there were significant reductions in serum levels of CRP ,IL‐6 and IL‐8 ,homeostasis model‐insulin resistance index (HOMA‐IR) and number of endothelial microparticles (EMPs) ,significant rise in in‐sulin sensitivity index (ISI) and flow‐mediated dilation of brachial artery (FMD) after treatment , P< 0.05 all . Compared with routine treatment group ,there were significant reductions in serum levels of CRP [ (67.27 ± 7.51) mg/L vs .(37.11 ± 6.32) mg/L] ,IL‐6 [ (87.58 ± 7.21)μg/L vs .(60.17 ± 5.45)μg/L] and IL‐8 [ (121.31 ± 8.57)μg/L vs .(84.44 ± 5.21)μg/L] ,HOMA‐IR [ (3.08 ± 0.51) vs .(2.31 ± 0.47)] and number of EMPs [ (852.18 ± 115.37) /μl vs .(573.29 ± 72.18)/μl] ,and significant rise in ISI [(-4.39 ± 0.61) vs .(-3.42 ± 0.53)] and FMD [ (4.35 ± 0.52)% vs .(5.82 ± 0.69)% ] in rosuvastatin group after treatment ,P<0.05 all .Conclusion:Rosuvasta‐tin could reduce inflammatory factor levels ,relieve insulin resistance and improve vascular endothelial function in patients with hypertension complicated dyslipidemia .
